

To Promote the Progress



of Science and Useful Arts

The Director

of the United States Patent and Trademark Office has received an application for a patent for a new and useful invention. The title and description of the invention are enclosed. The requirements of law have been complied with, and it has been determined that a patent on the invention shall be granted under the law.

Therefore, this United States

Patent

grants to the person(s) having title to this patent the right to exclude others from making, using, offering for sale, or selling the invention throughout the United States of America or importing the invention into the United States of America, and if the invention is a process, of the right to exclude others from using, offering for sale or selling throughout the United States of America, products made by that process, for the term set forth in 35 U.S.C. 154(a)(2) or (c)(1), subject to the payment of maintenance fees as provided by 35 U.S.C. 41(b). See the Maintenance Fee Notice on the inside of the cover.

Katherine Kelly Vidal

DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

Maintenance Fee Notice

If the application for this patent was filed on or after December 12, 1980, maintenance fees are due three years and six months, seven years and six months, and eleven years and six months after the date of this grant, or within a grace period of six months thereafter upon payment of a surcharge as provided by law. The amount, number and timing of the maintenance fees required may be changed by law or regulation. Unless payment of the applicable maintenance fee is received in the United States Patent and Trademark Office on or before the date the fee is due or within a grace period of six months thereafter, the patent will expire as of the end of such grace period.

Patent Term Notice

If the application for this patent was filed on or after June 8, 1995, the term of this patent begins on the date on which this patent issues and ends twenty years from the filing date of the application or, if the application contains a specific reference to an earlier filed application or applications under 35 U.S.C. 120, 121, 365(c), or 386(c), twenty years from the filing date of the earliest such application ("the twenty-year term"), subject to the payment of maintenance fees as provided by 35 U.S.C. 41(b), and any extension as provided by 35 U.S.C. 154(b) or 156 or any disclaimer under 35 U.S.C. 253.

If this application was filed prior to June 8, 1995, the term of this patent begins on the date on which this patent issues and ends on the later of seventeen years from the date of the grant of this patent or the twenty-year term set forth above for patents resulting from applications filed on or after June 8, 1995, subject to the payment of maintenance fees as provided by 35 U.S.C. 41(b) and any extension as provided by 35 U.S.C. 156 or any disclaimer under 35 U.S.C. 253.



US011771726B2

(12) **United States Patent**
Kwon(10) **Patent No.:** **US 11,771,726 B2**
(45) **Date of Patent:** **Oct. 3, 2023**(54) **COMPOSITION, CONTAINING QUISQUALIS INDICA EXTRACT, FOR PREVENTING OR TREATING PROSTATIC HYPERPLASIA**2012/0270837 A1 10/2012 Tripp et al.
2014/0349953 A1 11/2014 Nishida et al.
2016/0058782 A1 3/2016 Nishida et al.(71) Applicant: **The Industry & Academic Cooperation in Chungnam National University (IAC), Daejeon (KR)**(72) Inventor: **Hyo Jung Kwon, Yuseong-gu (KR)**(73) Assignee: **The Industry & Academic Cooperation in Chungnam National University, Daejeon (KR)**

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 28 days.

(21) Appl. No.: **16/725,608**(22) Filed: **Dec. 23, 2019**(65) **Prior Publication Data**

US 2020/0138886 A1 May 7, 2020

Related U.S. Application Data

(62) Division of application No. 15/574,702, filed as application No. PCT/KR2016/004653 on May 3, 2016, now abandoned.

(30) **Foreign Application Priority Data**

May 18, 2015 (KR) 10-2015-0069047

(51) **Int. Cl.****A61K 36/185** (2006.01)**A61P 13/08** (2006.01)(52) **U.S. Cl.**CPC **A61K 36/185** (2013.01); **A61P 13/08** (2018.01)(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited****U.S. PATENT DOCUMENTS**4,377,584 A 3/1983 Rasmussen et al.
4,760,071 A 7/1988 Rasmussen et al.
6,211,198 B1 * 4/2001 Gluchowski C07D 211/90
514/3187,084,274 B2 8/2006 Moon et al.
2002/0151503 A1 10/2002 Slusher et al.**FOREIGN PATENT DOCUMENTS**CN 1221346 A * 6/1999 A61K 31/00
CN 1221346 A 6/1999
CN 1883521 A 12/2006
CN 1020287789 A 4/2011
CN 103479978 A 1/2014
CN 104114176 A 10/2014
CN 104171635 A 12/2014
CN 104586664 A 5/2015
JP 3176983 B2 6/2001
JP 2003040769 A 2/2003
JP 2006-199609 A 8/2006
KR 1020130013712 2/2013
KR 1020150048495 5/2015**OTHER PUBLICATIONS**Sahu et al. ("Quisqualis indica Linn: A Review of its Medicinal Properties", *Int.J.Pharm.Phytopharmacol.Res.* 2012, 1(5): 313-321) (Year: 2012).*

International Search report in PCT/KR2016/004653, dated May 3, 2016.

U.S. Office action in U.S. Appl. No. 15/574,702 dated Mar. 19, 2019.

Charith UB Wijerathne et al., *Quisqualis indica* Improves Benign Prostatic Hyperplasia by Regulating Prostate Cell Proliferation and Apoptosis, 2017, *Biol. Pharm. Bull.*, vol. 40, pp. 2125-2133.

Qianliang, L., "Chinese Medicine", China Pharmaceutical Science and Technology Press, 1st Edition, Aug. 1992, 146-147.

Australian Government Department of Health and Ageing Therapeutic Goods Administration, CMEC 70 Complementary Medicines Evaluation Committee, Dec. 12, 2008.

Attachment 3, Item 7.1, CMEC 70 Complementary Medicines Evaluation Committee, Email correspondence to the TGA received from Dharamanada Subhuti, Oct. 2008.

* cited by examiner

Primary Examiner — Michael Barker*Assistant Examiner* — Randall O Winston(74) *Attorney, Agent, or Firm* — Schott, P.C.(57) **ABSTRACT**A pharmaceutical composition comprises a *Quisqualis indica* extract as an active ingredient, for preventing or treating prostatic hyperplasia, and may also be used in a food composition. The *Quisqualis indica* extract may be used to treat and prevent prostatic hyperplasia by exhibiting effects of a reduction in prostate weight, a reduction in DHT as a prostatic hyperplasia inducing factor, and a reduction in prostate epithelial cell hyperplasia.**5 Claims, 5 Drawing Sheets**

PATENT INFORMATION SHEET

Reference Numbers	
Our Reference Number	ONZ-P001-US-02
Your Reference Number	OVP1913223US
International Associate Reference Number	
Serial Number	16/725,608
Publication Number	20200138886
Patent Number	11,771,726
Country	United States
Dates	
Filing Date	December 23, 2019
Publication Date	May 7, 2020
Issue Date	October 3, 2023
Expiration Date	
Priority Date	May 18, 2015
Title and Inventor(s)	
Title	COMPOSITION, CONTAINING QUISAQUALIS INDICA EXTRACT, FOR PREVENTING OR TREATING PROSTATIC HYPERPLASIA
Inventor 1 Address	Hyo Jung Kwon 102-1004, Songnim maeul Apt., 13 Songnim-ro, Yuseong-gu, Daejeon 305-759 Republic of Korea
Assignment Information	
Assignee Address	The Industry & Academic Cooperation in Chungnam National University (IAC) 99, Daehak-ro Yuseong-gu, Daejeon 34134 Republic of Korea
Recorded at Reel/Frame	052054/0938